期刊文献+

乙型肝炎病毒RT区原发性耐药变异的研究 被引量:4

Study on primary drug resistance mutation in the reverse transcriptase region of hepatitis B virus
下载PDF
导出
摘要 目的探讨核苷(酸)类似物(NA)治疗前乙型肝炎病毒(HBV)RT区原发性耐药变异的发生情况。方法采用PCR产物直接测序技术对61例未接受NA治疗的慢性HBV感染者进行HBV RT区序列测定,分析NA治疗前HBV RT区原发性耐药变异的发生率。结果通过HBV基因扩增、PCR产物直接测序后,共获得61个HBV RT区基因序列,采用HBV RT区基因进化树基因分型共分出B型42例(42/61,68.85%),C型19例(19/61,31.15%),未检出其他基因型。通过核苷酸序列及氨基酸序列分析,对NA常见的10个耐药变异位点(rtI169T、rtV173L、rtL180M、rtA181V/T、rtT184G/S/A/I、rtA194T、rtS202I/G、rtM204I/V、rtN236T、rtM250V)进行比对后,61例患者中共检出HBV RT区变异3例(rtM204I 2例,rtM204I+L180M 1例),自然耐药变异的检出率为4.92%。结论慢性HBV感染者存在少量RT区原发性耐药变异位点,与原发性无应答有关。 Objective To explore the occurrence of primary drug resistance mutation in the reverse transcriptase(RT) region of hepatitis B virus(HBV) before nucleotide(acid) analogue(NA) treatment.Methods HBV RT region sequence of 61 NA-untreated patients with chronic HBV infection that were determined by direct sequencing incidence of primary drug resistance mutation before NA administration was analyzed.Results 61 sequences of HBV RT region were gained by gene amplification and direct sequencing PCR products.Phylogenetic tree analysis of HBV RT region revealed 42 cases of genotype B(42/61,68.85%)and 19 cases of genotype C(19/61,31.15%)and no other genotype was detected.After nucleotide sequence and amino acid sequence analyzed,3 patients were detected mutation in the RT region(2 rtM204I and 1 rtM204I+L180M) by comparative analysis with 10 common mutation sites of resistance(rtI169T,rtV173L,rtL180M,rtA181V/T,rtT184G/S/A/I,rtA194T,rtS202I/G,rtM204I/V,rtN236T and rtM250V).The relevance ratio of primary drug resistance mutation was 4.92%.Conclusion Small amounts of primary drug resistance mutations have been found in RT region of patients with chronic HBV infection,which was correlated with primary non-response.
机构地区 解放军第 解放军第
出处 《胃肠病学和肝病学杂志》 CAS 2012年第10期927-929,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 乙型肝炎病毒 原发性耐药 变异 碱基序列 Hepatitis B virus Primary drug resistance Mutation Base sequence
  • 相关文献

参考文献6

  • 1Luearnini S. Primary resistance, muhidrug resistance, and cross-resist- ance pathways in HBV as a consequence of treatment failure [J]. Hep- atol Int, 2008, 2(2) : 147-151.
  • 2European Association For The Study Of The Liver. EASL clinical prac- tice guidelines: management of chronic hapatitis B virus infection [ J]. J Hepatol, 2012, 57(1): 167-185.
  • 3Sifildgen O, Sinna H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir [J]. N Engl J Med, 2006, 354(17) : 1807-1812.
  • 4Santantonio T, Fasano M, Durantel S, et al. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepalitis B [ J ]. Antivir Ther, 2009, 14(4) : 557-565.
  • 5赵磊.拉米夫定治疗前与治疗期间乙肝病毒YMDD变异研究[J].中阁热带医学,2009,9(3):410-411.
  • 6娄红梅,钟细涛,李志国,李清旺,刘柱,尹林峰.乙型肝炎病毒基因自然变异耐药性的研究[J].中华肝脏病杂志,2011,19(11):868-869. 被引量:3

二级参考文献2

  • 1Lok ASF. Hepatitis B virus resistance for clinicians. Ganzang, 2007, 12: 43-45. (in Chinese).
  • 2Aebersold R, Goodlett D. Mass spectrometry in proteomics. Chem Rev,2001,101:269 - 295

共引文献2

同被引文献39

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部